Los Angeles Capital Management
EDIT icon

Los Angeles Capital Management’s Editas Medicine EDIT Stock Holding History

Los Angeles Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879K Buy
271,186
+130,758
+93% +$382K ﹤0.01% 773
2026
Q1 		$347K Buy
140,428
+42,625
+44% +$90.2K ﹤0.01% 981
2025
Q4 		$294K Sell
97,803
-19,873
-17% -$57.4K ﹤0.01% 1109
2025
Q3 		$408K Sell
117,676
-18,289
-13% -$51K ﹤0.01% 1003
2025
Q2 		$299K Sell
135,965
-26,165
-16% -$42.8K ﹤0.01% 1047
2025
Q1 		$188K Buy
162,130
+63,291
+64% +$93.1K ﹤0.01% 1027
2024
Q4 		$126K Sell
98,839
-18,800
-16% -$47.9K ﹤0.01% 1082
2024
Q3 		$401K Sell
117,639
-13,310
-10% -$57.9K ﹤0.01% 924
2024
Q2 		$612K Sell
130,949
-16,934
-11% -$95.5K ﹤0.01% 802
2024
Q1 		$1.1M Buy
+147,883
New +$1.23M ﹤0.01% 667
2022
Q4 		– Sell
-36,453
Closed -$446K – 1210
2022
Q3 		$446K Buy
36,453
+387
+1% +$6.03K ﹤0.01% 954
2022
Q2 		$427K Buy
36,066
+4,177
+13% +$56K ﹤0.01% 1022
2022
Q1 		$607K Buy
31,889
+15,745
+98% +$293K ﹤0.01% 957
2021
Q4 		$429K Sell
16,144
-167
-1% -$5.75K ﹤0.01% 1080
2021
Q3 		$670K Hold
16,311
– – ﹤0.01% 923
2021
Q2 		$924K Sell
16,311
-3,940
-19% -$146K ﹤0.01% 898
2021
Q1 		$851K Sell
20,251
-18,601
-48% -$1.06M ﹤0.01% 966
2020
Q4 		$2.72M Sell
38,852
-6,790
-15% -$279K 0.01% 566
2020
Q3 		$1.28M Sell
45,642
-13,890
-23% -$452K 0.01% 728
2020
Q2 		$1.76M Sell
59,532
-3,070
-5% -$80.2K 0.01% 641
2020
Q1 		$1.24M Buy
62,602
+4,105
+7% +$104K 0.01% 656
2019
Q4 		$1.73M Buy
+58,497
New +$1.46M 0.01% 682
2019
Q3 		– Sell
-12,705
Closed -$314K – 1285
2019
Q2 		$314K Sell
12,705
-5,220
-29% -$125K ﹤0.01% 1175
2019
Q1 		$438K Buy
+17,925
New +$406K ﹤0.01% 1122

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Los Angeles Capital Management's EDIT Position: Q2 2026 in Review

Los Angeles Capital Management increased its Editas Medicine (EDIT) stake by 93% in Q2 2026, buying an estimated $382K and bringing the position to 271,186 shares worth $879K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Los Angeles Capital Management first reported a position in EDIT in Q1 2019 and has held it in 24 quarters since. The position peaked at $2.72M in Q4 2020. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Los Angeles Capital Management held 271,186 shares of Editas Medicine worth $879K as of Q2 2026.
  • Los Angeles Capital Management bought 130,758 Editas Medicine shares in Q2 2026, an estimated $382K.
  • Editas Medicine made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #773 holding.
  • Los Angeles Capital Management first reported a position in Editas Medicine in Q1 2019 and has held it in 24 quarters since.
  • Los Angeles Capital Management's Editas Medicine position peaked at $2.72M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.